WallStreetZenWallStreetZen

NASDAQ: MDGL
Madrigal Pharmaceuticals Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

MDGL earnings and revenue history

Current Revenue
$0.0
Current Earnings
-$373.6M
Current Profit Margin
0%

MDGL Return on Equity

Current Company
-219.4%
Current Industry
-63.5%
Current Market
188%
MDGL's Return on Equity (-219.4%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when MDGL announces earnings.

MDGL Return on Assets

Current Company
-98.8%
Current Industry
2.9%
MDGL is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

MDGL Return on Capital Employed

Current Company
-69.14%
Current Industry
19.5%
MDGL has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

MDGL vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
MDGL$0.00-$360.39M-$373.63MN/AN/A
ALPN$58.88M-$31.41M-$32.18M+142.30%N/A
IMVT$0.00-$242.72M-$243.45MN/AN/A
NUVL$0.00-$126.22M-$126.22MN/AN/A
BBIO$9.30M-$551.39M-$643.20M-30.80%N/A
View Top Biotech Stocks

MDGL earnings dates

Next earnings date
May 7, 2024

Madrigal Pharmaceuticals Earnings & Revenue FAQ

What were MDGL's earnings last quarter?

On Invalid Date, Madrigal Pharmaceuticals (NASDAQ: MDGL) reported Q4 2023 earnings per share (EPS) of -$5.72, up 14.86% year over year. Total Madrigal Pharmaceuticals earnings for the quarter were -$112.19 million. In the same quarter last year, Madrigal Pharmaceuticals's earnings per share (EPS) was -$4.98.

If you're new to stock investing, here's how to buy Madrigal Pharmaceuticals stock.

What was MDGL's earnings growth in the past year?

As of Q2 2024, Madrigal Pharmaceuticals's earnings has grown year over year. Madrigal Pharmaceuticals's earnings in the past year totalled -$373.63 million.

What is MDGL's earnings date?

Madrigal Pharmaceuticals's earnings date is Invalid Date. Add MDGL to your watchlist to be reminded of MDGL's next earnings announcement.

What was MDGL's revenue last quarter?

On Invalid Date, Madrigal Pharmaceuticals (NASDAQ: MDGL) reported Q4 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Madrigal Pharmaceuticals's revenue was $0.00.

What was MDGL's revenue growth in the past year?

As of Q2 2024, Madrigal Pharmaceuticals's revenue has grown null year over year. Madrigal Pharmaceuticals's revenue in the past year totalled $0.00.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.